Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. (2015)
Attributed to:
Infrastructure for collaboration: Leeds MRC Medical Bioinformatics Centre
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s10549-015-3633-7
PubMed Identifier: 26567010
Publication URI: http://europepmc.org/abstract/MED/26567010
Type: Journal Article/Review
Volume: 154
Parent Publication: Breast cancer research and treatment
Issue: 3
ISSN: 0167-6806